Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC) has received an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $29.14.

Several equities analysts recently commented on BCYC shares. JMP Securities dropped their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. B. Riley cut their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. Stephens reaffirmed an “equal weight” rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th.

Insiders Place Their Bets

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. The trade was a 7.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Alistair Milnes sold 4,578 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $64,504.02. Following the sale, the chief operating officer now directly owns 100,724 shares in the company, valued at approximately $1,419,201.16. The trade was a 4.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,677 shares of company stock worth $392,413 over the last three months. Company insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its position in Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after purchasing an additional 32,313 shares during the last quarter. FMR LLC bought a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $3,406,000. Erste Asset Management GmbH purchased a new stake in shares of Bicycle Therapeutics in the 3rd quarter worth approximately $325,000. HighVista Strategies LLC boosted its position in Bicycle Therapeutics by 9.7% during the 3rd quarter. HighVista Strategies LLC now owns 139,544 shares of the company’s stock valued at $3,158,000 after acquiring an additional 12,289 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Bicycle Therapeutics by 1,438.1% during the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock valued at $20,362,000 after purchasing an additional 841,299 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

Shares of Bicycle Therapeutics stock opened at $7.85 on Wednesday. The firm has a market cap of $543.24 million, a PE ratio of -2.39 and a beta of 1.12. Bicycle Therapeutics has a 1 year low of $7.85 and a 1 year high of $28.67. The stock has a fifty day moving average price of $11.23 and a 200-day moving average price of $17.32.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm’s quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.16) earnings per share. As a group, equities analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.